Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Substituted benzopyrans as selective estrogen receptor-beta agonists

a technology of benzopyran and benzopyran, which is applied in the direction of heterocyclic compound active ingredients, biocide, drug compositions, etc., can solve the problems of increased urination frequency, poor urine stream, hesitation or delay in starting the urine flow,

Inactive Publication Date: 2007-10-09
ELI LILLY & CO
View PDF10 Cites 30 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about new compounds called benzopyran derivatives that can be used to treat diseases such as prostate cancer, cardiovascular diseases, and urinary incontinence. These compounds are particularly effective at interacting with a protein called estrogen receptor beta. The invention includes several specific compounds, as well as pharmaceutical compositions and medical methods for using them as therapeutic agents.

Problems solved by technology

This results in increased frequency of urination, noncuria, poor urine stream, and hesitation or delay in starting the urine flow.
Consequences of BPH can include hypertrophy of bladder smooth muscle, decompensated bladder, and increased incidence of urinary tract infection.
These approaches are of limited therapeutic benefit.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Substituted benzopyrans as selective estrogen receptor-beta agonists
  • Substituted benzopyrans as selective estrogen receptor-beta agonists
  • Substituted benzopyrans as selective estrogen receptor-beta agonists

Examples

Experimental program
Comparison scheme
Effect test

preparation 1

Preparation of 1,3-dibromo-2,5-bis-methoxymethoxy-benzene

[0042]

A. Preparation of 2,6-dibromo-4-methoxy-phenol

[0043]

[0044]To 4-methoxyphenol (10.00 g, 80.6 mmol) in CH2Cl2 (70 mL), add a stirred solution of benzyltrimethylammonium tribromide (69.10 g, 177.2 mmol) in CH2Cl2 (500 mL) and MeOH (200 mL). Stir the reaction for 12 hours and remove the solvent in vacuo. Add methyl tert-butyl ether (MTBE) (600 mL) and collect the precipitate (benzyltrimethylammonium bromide) by filtration and wash with MTBE (200 mL). Filter the organics through Celite® and concentrate to provide the subtitled product (23.0 g, >95%) as an orange solid that may be used without purification. 1H NMR (DMSO-d6) δ 3.69 (s, 3H), 7.14 (s, 2H), 9.32 (s, 1H).

B. Preparation of 2,6-dibromo-benzene-1,4-diol

[0045]

[0046]Dissolve 2,6-dibromo-4-methoxyphenol (23.0 g, 80.6 mmol) in CH3CN (400 mL) and add trimethylsilyl iodide (TMSI) (53 mL, 371 mmol). Reflux the solution for 4 hours and add more TMSI (50 mL, 371 mmol). Heat th...

preparation 2

Preparation of 2-trifluoromethanesulfonyloxy-cyclopent-1-enecarboxylic acid methyl ester

[0049]

[0050]Slowly add a solution of methyl 2-oxocyclopentanecarboxylate (21.0 g, 148 mmol) in CH2Cl2 (30 mL) to a −78° C. solution of N,N,-diisopropylethylamine (DIPEA) (129 mL, 738 mmol) in CH2Cl2 (670 mL). Keep the reaction temperature below −65° C. Then slowly add a solution of trifluoromethanesulfonic anhydride (50.0 g, 177 mmol) in CH2Cl2 (30 mL) to the reaction, keeping the reaction temperature below −65° C. After 1.5 hours, quench the reaction with H2O (500 mL) and warm to room temperature. Separate the layers and extract the aqueous layer with CH2Cl2 (2×100 mL). Combine the organic extracts, dry (Na2SO4), filter and concentrate. Pre-absorb the crude material onto silica gel. Purify using silica gel chromatography, eluting with Hex:EtOAc (90:10) to provide the title product (34.3 g, 85%) as a light yellow oil. 1H NMR (CDCl3) δ 1.97-2.07 (m, 2H), 2.68-2.78 (m, 4H), 3.79 (s, 3H). CIMS (Meth...

preparation 3

Preparation of 1-Bromo-4-methoxymethoxy-benzene

[0051]

[0052]Add sodium hydride (2.78 g of 95% dry, 0.116 mol) in portions to a 500 mL three-necked flask equipped with a nitrogen inlet, magnetic stir bar and DMF (200 mL) at −10 to −15° C. Add a solution of 4-bromophenol (20.00 g, 0.116 mol) in DMF (100 mL) over about 20 minutes, maintaining the internal temperature of the reaction below −5° C. Stir the reaction for 1 hour and then add MOMCl (8.81 mL, 0.116 mol) in portions to maintain the internal temperature below −5° C. Stir the mixture for 3 hours and then add ice until gas evolution ceases. Pour the reaction into ice-H2O (500 mL) and extract with EtOAc (2×300 mL). Wash the combined organic extracts with 1 N NaOH (500 mL), H2O (500 mL) and brine (400 mL). Dry the solution (MgSO4), filter and concentrate to obtain the title product (23.94 g, 93%) as an oil which may be used without further purification. 1H NMR (CDCl3) δ 3.46 (s, 3H), 5.14 (s, 2H), 6.92 (d, J =9.0 Hz, 2H), 7.37 (d, J...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

The present invention relates to substituted benzopyran derivatives, stereoisomers, and pharmaceutical acceptable salts thereof and processes for the preparation of the same. The compounds of the present invention are useful as Estrogen Receptor ? agonists. Such agonists are useful for the treating Estrogen Receptor ? mediated diseases such as prostate cancer or BPH.

Description

BACKGROUND OF THE INVENTION[0001]The present invention relates to novel cycloalkyl-benzopyrans and derivatives thereof, compositions containing those compounds, their use as selective estrogen receptor-beta agonists, and their use in the treatment of estrogen receptor-beta mediated diseases such as prostate cancer, benign prostatic hyperplasia (hypertrophy), testicular cancer, ovarian cancer, lung cancer, cardiovascular diseases, neurodegenerative disorders, urinary incontinence, central nervous system (CNS) disorders, gastrointestinal (GI) tract disorders, and osteoporosis.[0002]Estrogens play important roles in the development and homeostasis of the reproductive, central nervous, skeletal, and cardiovascular systems of both males and females. Recently, a new ER isoform, ER-beta (also known as ER-beta1) was cloned from a rat prostatic cDNA library and is present in murine and human prostates. Consequently, the previous ER is now designated as ER-alpha. ER-alpha and ER-beta share hi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): C07D311/76C07D311/94A61P35/00
CPCC07D311/94A61P35/00
Inventor DURST, GREGORY LEENORMAN, BRYAN HURSTPFEIFER, LANCE ALLENRICHARDSON, TIMOTHY IVO
Owner ELI LILLY & CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com